Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Clinical Trial of CRX-100 in Therapy-Refractory Solid Tumors Including Ovarian Cancer

Trial Profile

A Phase 1b/2a Clinical Trial of CRX-100 in Therapy-Refractory Solid Tumors Including Ovarian Cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRX 100 (Primary)
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioEclipse Therapeutics
  • Most Recent Events

    • 24 Jun 2019 According to a BioEclipse Therapeutics media release, the company plans to use proceeds from the Series A-1 financing to initiate this trial.It expects to file an Investigational New Drug application (IND) with the U.S. Food and Drug Administration by the end of 2019 and plans to initiate this trial during the first quarter of 2020.
    • 11 Sep 2018 According to a BioEclipse Therapeutics company website, this study is expected to start in 2018.
    • 11 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top